Company news

Rein Therapeutics, Inc. news in 2021

Rein Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs

December 19, 2021

Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

November 11, 2021

Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity

October 6, 2021

Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021

September 29, 2021

Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent

September 15, 2021

Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference

September 6, 2021

Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting

August 26, 2021

Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

August 10, 2021

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021

July 7, 2021

Aileron Therapeutics to be Added to the Russell Microcap® Index

June 23, 2021

Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities

May 18, 2021

Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 10, 2021

Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

March 23, 2021

Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference

March 3, 2021

Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

March 1, 2021

Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners

January 10, 2021

Aileron Therapeutics Announces $35.9 Million Registered Direct Offering

January 5, 2021